The global skin cancer diagnostics market size was estimated at USD 9.58 billion in 2024 and is projected to reach USD 15.67 billion by 2033, growing at a CAGR of 5.7% from 2025 to 2033. The integration of artificial intelligence, technological advancements, and patient preference for non-invasive diagnostics drives the growth.
Furthermore, increased awareness about skin cancer, advancements in AI-based diagnostic tools, and initiatives promoting early detection, rising incidence, particularly in sun-exposed regions, are expected to drive the market growth. For instance, according to the American Cancer Society, invasive melanoma accounts for only 1% of all skin cancer cases, and in 2024, an estimated 100,640 new cases of invasive and 99,700 cases of in situ melanoma were diagnosed in the U.S. Partnerships between healthcare providers and tech companies further support this growth by enhancing accessibility and accuracy of diagnoses.
Furthermore, advanced technologies such as AI-enabled product approvals are driving the growth of the market. For instance, in January 2024, the FDA approved the first AI-powered skin cancer diagnostic tool, namely the DermaSensor device. Further, DermaSensor provides quantitative, point-of-testing identification for skin cancer, including melanoma, squamous cell carcinoma, and basal cell carcinoma. Also, the DermaSensor device uses artificial intelligence (AI)-powered spectroscopy in order to identify cellular and subcellular characteristics of lesions.
Modern machine learning techniques rely on extensive datasets to identify patterns useful for classification, with diagnostic imaging being a particularly promising area for AI research. Moreover, skin cancer detection, in particular, is an attractive test type for AI due to the subjective nature of clinical and dermoscopic image interpretation. Also, AI-assisted diagnosis offers advantages such as improved access to specialist expertise, which is often scarce in many regions, leading to long waiting times for specialist appointments. There is growing optimism that AI-based systems could offer greater consistency and higher accuracy than human experts.
This product will be delivered within 1-3 business days.
Furthermore, increased awareness about skin cancer, advancements in AI-based diagnostic tools, and initiatives promoting early detection, rising incidence, particularly in sun-exposed regions, are expected to drive the market growth. For instance, according to the American Cancer Society, invasive melanoma accounts for only 1% of all skin cancer cases, and in 2024, an estimated 100,640 new cases of invasive and 99,700 cases of in situ melanoma were diagnosed in the U.S. Partnerships between healthcare providers and tech companies further support this growth by enhancing accessibility and accuracy of diagnoses.
Furthermore, advanced technologies such as AI-enabled product approvals are driving the growth of the market. For instance, in January 2024, the FDA approved the first AI-powered skin cancer diagnostic tool, namely the DermaSensor device. Further, DermaSensor provides quantitative, point-of-testing identification for skin cancer, including melanoma, squamous cell carcinoma, and basal cell carcinoma. Also, the DermaSensor device uses artificial intelligence (AI)-powered spectroscopy in order to identify cellular and subcellular characteristics of lesions.
Modern machine learning techniques rely on extensive datasets to identify patterns useful for classification, with diagnostic imaging being a particularly promising area for AI research. Moreover, skin cancer detection, in particular, is an attractive test type for AI due to the subjective nature of clinical and dermoscopic image interpretation. Also, AI-assisted diagnosis offers advantages such as improved access to specialist expertise, which is often scarce in many regions, leading to long waiting times for specialist appointments. There is growing optimism that AI-based systems could offer greater consistency and higher accuracy than human experts.
Global Skin Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global skin cancer diagnostics market report based on cancer type, test type, end use, and region:Cancer Type Outlook (Revenue, USD Million; 2021-2033)
- Melanoma
- Non-Melanoma
Test Type Outlook (Revenue, USD Million; 2021-2033)
- Dermatoscopy
- Skin Biopsy
- Lymph node biopsy
- Imaging Tests
- Others
End Use Outlook (Revenue, USD Million; 2021-2033)
- Hospital and Clinics
- Laboratories
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa (MEA)
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Report Deliverables
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Skin Cancer Diagnostics Market Variables, Trends & Scope
Chapter 4. Skin Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis
Chapter 5. Skin Cancer Diagnostics Market: Test Type Estimates & Trend Analysis
Chapter 6. Skin Cancer Diagnostics Market: End Use Estimates & Trend Analysis
Chapter 7. Skin Cancer Diagnostics Market: Regional Estimates & Trend Analysis by Cancer Type, Test Type, and End Use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Skin Cancer Diagnostics market report include:- Castle Bioscience
- DermTech
- bioMérieux Inc.
- FOUNDATION MEDICINE, INC.
- DermaSensor, Inc.
- F Hoffmann-La Roche Ltd
- NeoGenomics Laboratories
- Quest Diagnostics Incorporated.
- SkylineDx
- Abbott
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 125 |
| Published | October 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 9.58 Billion |
| Forecasted Market Value ( USD | $ 15.67 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
